Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.
第一作者:
Andrew,Chang
作者:
医学主题词
人类(Humans);重组融合蛋白质类(Recombinant Fusion Proteins);受体, 血管内皮生长因子(Receptors, Vascular Endothelial Growth Factor);玻璃体内注射(Intravitreal Injections);男(雄)性(Male);女(雌)性(Female);老年人(Aged);视敏度(Visual Acuity);中年人(Middle Aged);湿性黄斑变性(Wet Macular Degeneration);血管生成抑制剂(Angiogenesis Inhibitors);治疗结果(Treatment Outcome);体层摄影术, 光学相干(Tomography, Optical Coherence);剂量效应关系, 药物(Dose-Response Relationship, Drug);老年人, 80以上(Aged, 80 and over);随访研究(Follow-Up Studies);双盲法(Double-Blind Method);血管内皮生长因子A(Vascular Endothelial Growth Factor A);时间因素(Time Factors);荧光素血管造影术(Fluorescein Angiography)
DOI
10.1016/j.apjo.2026.100278
PMID
41519383
发布时间
2026-01-30
- 浏览0
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
100278页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



